- 01Artrya inks five-year, US$0.5m-minimum HonorHealth deal.
- 02Salix rollout spans nine hospitals serving ~5m people.
- 03HonorHealth is Artrya’s fifth US customer.
Artrya (ASX: AYA) has signed a five-year commercial agreement with Arizona healthcare group HonorHealth for its Salix Coronary Anatomy software, carrying a minimum contracted value of US$0.5 million.
The deal makes HonorHealth the Australian medical technology developer’s fifth US commercial customer and its first inbound customer outside its foundation customer and SAPPHIRE research networks.
Salix will be deployed across nine acute-care hospitals offering coronary computed tomography angiography (CCTA), extending the platform into a health system serving approximately five million people.
The agreement follows the recent conversion of Huntsville Health from a SAPPHIRE study partner into a commercial customer, giving Artrya another channel for US adoption.
Recurring SaaS Revenue
The five-year contract provides recurring software-as-a-service (SaaS) subscription revenue from Salix Coronary Anatomy, with further revenue potential tied to the use of additional assessment modules.
Salix Coronary Plaque can generate fee-per-scan revenue, while fees from Salix Coronary Flow remain contingent on clearance from the US Food and Drug Administration.
The US$0.5m minimum applies only to Salix Coronary Anatomy and excludes potential usage-based receipts from the Plaque and Flow products.
The contract includes customary terms covering defaults, security and privacy requirements, support and software upgrades.
Network Deployment at Scale
HonorHealth operates nine acute-care hospitals in the Phoenix and Scottsdale metropolitan areas, supported by HonorHealth Heart Care’s network of 40 cardiac specialist offices.
The wider non-profit system encompasses 200 primary, specialist and urgent care locations, with more than 17,000 team members and 4,000 medical staff.
Before the agreement, clinical, technical and information technology teams undertook a detailed demonstration and validation of Salix within HonorHealth Heart Care.
That evaluation was led by HonorHealth network director of advanced medical imaging Dr Joshua Kim and preceded the planned system-wide integration.
The expanded footprint provides a test of how Salix performs across a large hospital network rather than within a single clinical site.
Wider Clinical Adoption
HonorHealth intends to use Salix to support a larger CCTA program, with an initial emphasis on integrating the platform into existing clinical workflows, and the parties envisage wider physician adoption, increased scanning capacity, and greater use of the coronary assessment modules as implementation progresses.
Over the longer term, they plan to explore a cardiovascular imaging Centre of Excellence in Arizona that could support clinical evidence, education, and training.
The relationship could also create research opportunities through HonorHealth’s role as primary clinical affiliate of Arizona State University’s John Shufeldt School of Medicine and Medical Engineering.
“HonorHealth is an exciting customer for Artrya, a major US health system with a strong focus on using advanced medical imaging technology to improve clinical workflows and patient care,” Artrya chief executive officer John Konstantopoulos said.
“Our immediate focus is now on successful implementation and driving clinical adoption across the HonorHealth network.”
Get the wire before the market opens.
The ASX small-cap stories that matter, filed before 9am AEST. Curated by the Small Caps desk.